JP7590996B2 - Egfr阻害剤としての新たな大環状化合物および誘導体 - Google Patents
Egfr阻害剤としての新たな大環状化合物および誘導体 Download PDFInfo
- Publication number
- JP7590996B2 JP7590996B2 JP2021576576A JP2021576576A JP7590996B2 JP 7590996 B2 JP7590996 B2 JP 7590996B2 JP 2021576576 A JP2021576576 A JP 2021576576A JP 2021576576 A JP2021576576 A JP 2021576576A JP 7590996 B2 JP7590996 B2 JP 7590996B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- alkylene
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181952 | 2019-06-24 | ||
| EP19181952.3 | 2019-06-24 | ||
| PCT/EP2020/067451 WO2020260252A1 (en) | 2019-06-24 | 2020-06-23 | New macrocyclic compounds and derivatives as egfr inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538228A JP2022538228A (ja) | 2022-09-01 |
| JP2022538228A5 JP2022538228A5 (cg-RX-API-DMAC7.html) | 2023-06-26 |
| JP7590996B2 true JP7590996B2 (ja) | 2024-11-27 |
Family
ID=67003267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576576A Active JP7590996B2 (ja) | 2019-06-24 | 2020-06-23 | Egfr阻害剤としての新たな大環状化合物および誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12522615B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986564A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7590996B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114007698B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020260252A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220114615A (ko) | 2019-12-16 | 2022-08-17 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Egfr 키나제의 분해를 억제 및 유도하는 화합물 |
| CN113880804A (zh) * | 2020-07-01 | 2022-01-04 | 微境生物医药科技(上海)有限公司 | 新型苯并咪唑化合物 |
| CN114163454B (zh) * | 2020-09-11 | 2026-01-02 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物抑制剂、其制备方法和应用 |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| CN114057771B (zh) * | 2020-12-03 | 2023-10-03 | 北京鞍石生物科技有限责任公司 | 大环化合物及其制备方法和应用 |
| CN114656482B (zh) * | 2020-12-23 | 2025-10-17 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
| CN114907379B (zh) * | 2021-02-06 | 2026-04-17 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的大环化合物 |
| CN116761603A (zh) * | 2021-02-06 | 2023-09-15 | 正大天晴药业集团股份有限公司 | 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途 |
| US20240166665A1 (en) * | 2021-03-02 | 2024-05-23 | Dana-Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
| WO2022204544A1 (en) * | 2021-03-26 | 2022-09-29 | Theseus Pharmaceuticals, Inc. | Macrocyclic egfr inhibitors for the treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| AU2022272190A1 (en) * | 2021-05-11 | 2023-11-23 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2022242712A1 (zh) * | 2021-05-21 | 2022-11-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的大环化合物及包含该化合物的组合物及其用途 |
| CN115433207A (zh) * | 2021-06-03 | 2022-12-06 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
| JP2024527464A (ja) * | 2021-06-30 | 2024-07-25 | アキリオン アーベー | 大環状tak1阻害剤 |
| WO2023001069A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 大环酰胺类化合物及其应用 |
| AU2022402875A1 (en) * | 2021-11-30 | 2024-06-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Compound containing cycloalkyl or haloalkyl |
| WO2023205595A2 (en) * | 2022-04-20 | 2023-10-26 | Celyn Therapeutics, Inc | Egfr inhibitors in cancer treatment |
| CN117024443A (zh) * | 2022-05-09 | 2023-11-10 | 元启(苏州)生物制药有限公司 | Egfr抑制剂及其用途 |
| CN119522227A (zh) * | 2022-07-21 | 2025-02-25 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| WO2024016986A1 (zh) | 2022-07-21 | 2024-01-25 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| TW202416963A (zh) * | 2022-09-02 | 2024-05-01 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Egfr抑制劑及其用途 |
| WO2024078263A1 (zh) * | 2022-10-09 | 2024-04-18 | 药雅科技(上海)有限公司 | 大环杂环类化合物作为egfr抑制剂的制备及其应用 |
| CN117229300A (zh) * | 2023-03-12 | 2023-12-15 | 药雅科技(上海)有限公司 | Egfr抑制剂的制备及其应用 |
| WO2024099400A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| WO2024099402A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| AR131026A1 (es) * | 2022-11-10 | 2025-02-12 | Beigene Ltd | Compuestos para la degradación de la egfr quinasa |
| CN118324778B (zh) * | 2023-04-25 | 2026-08-11 | 苏州共康医药科技有限公司 | 第四代egfr抑制剂 |
| WO2024246838A1 (en) * | 2023-05-31 | 2024-12-05 | Beigene Switzerland Gmbh | Compounds for the degradation of egfr kinase |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015518895A (ja) | 2012-06-06 | 2015-07-06 | アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc | Egfr活性を調節するための化合物および組成物 |
| JP2015518894A (ja) | 2012-06-06 | 2015-07-06 | アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc | Egfr活性を調節するための化合物および組成物 |
| JP2016507539A (ja) | 2013-02-07 | 2016-03-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 大環状ピリダジノン誘導体 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1434579B1 (en) | 2001-10-09 | 2011-06-08 | Amgen Inc. | Imidazole derivatives as antiinflammatory agents |
| EA200400595A1 (ru) | 2001-11-09 | 2004-10-28 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JP2005536533A (ja) | 2002-08-08 | 2005-12-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換ベンゾイミダゾール化合物 |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| WO2005079791A1 (en) | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| US20110071130A1 (en) | 2006-05-08 | 2011-03-24 | Pharmacopeia, Inc. | 2-aminobenzimidazoles for treating neurodegenerative diseases |
| SG10201505997TA (en) | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| CN103159742B (zh) * | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| EP2890691B1 (en) | 2012-08-31 | 2018-04-25 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| CA2943231C (en) | 2014-03-20 | 2023-10-24 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| IL291000B2 (en) | 2014-03-20 | 2024-04-01 | Capella Therapeutics Inc | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| WO2016176473A1 (en) | 2015-04-28 | 2016-11-03 | Sanford-Burnham Medical Researc Institute | Apelin receptor agonists and methods of use thereof |
| WO2016185333A1 (en) | 2015-05-15 | 2016-11-24 | Novartis Ag | Methods for treating egfr mutant cancers |
| HK1252693A1 (zh) | 2015-06-30 | 2019-05-31 | Dana Farber Cancer Institute, Inc. | Egfr抑制剂及其使用方法 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| KR102670695B1 (ko) | 2015-09-18 | 2024-06-05 | 메르크 파텐트 게엠베하 | Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도 |
| ES2911888T3 (es) | 2015-09-18 | 2022-05-23 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos |
| CN109789143A (zh) * | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| US11083793B2 (en) | 2016-12-13 | 2021-08-10 | Health Research, Inc. | Epidermal growth factor receptor (EGFR) targeted photosensitizers |
-
2020
- 2020-06-23 US US17/621,420 patent/US12522615B2/en active Active
- 2020-06-23 JP JP2021576576A patent/JP7590996B2/ja active Active
- 2020-06-23 CN CN202080045795.1A patent/CN114007698B/zh active Active
- 2020-06-23 WO PCT/EP2020/067451 patent/WO2020260252A1/en not_active Ceased
- 2020-06-23 EP EP20734188.4A patent/EP3986564A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015518895A (ja) | 2012-06-06 | 2015-07-06 | アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc | Egfr活性を調節するための化合物および組成物 |
| JP2015518894A (ja) | 2012-06-06 | 2015-07-06 | アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc | Egfr活性を調節するための化合物および組成物 |
| JP2016507539A (ja) | 2013-02-07 | 2016-03-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 大環状ピリダジノン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022538228A (ja) | 2022-09-01 |
| CN114007698A (zh) | 2022-02-01 |
| EP3986564A1 (en) | 2022-04-27 |
| CN114007698B (zh) | 2024-01-09 |
| WO2020260252A1 (en) | 2020-12-30 |
| US20220380382A1 (en) | 2022-12-01 |
| US12522615B2 (en) | 2026-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12522615B2 (en) | Macrocyclic compounds and derivatives as EGFR inhibitors | |
| JP7808056B2 (ja) | がんを治療するための縮合環化2-アミノ-3-シアノチオフェン及び誘導体 | |
| JP7313364B2 (ja) | Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体 | |
| WO2023099612A1 (en) | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | |
| JP2024543975A (ja) | 癌の処置のための環化2-アミノ-3-シアノチオフェン及び誘導体 | |
| CN116507627B (zh) | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 | |
| EP3464267A1 (en) | New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors | |
| JP2021505598A (ja) | 心不全およびそれに関連する障害の治療または予防に有用なβ−3アドレナリン受容体のモジュレーター | |
| EP3691642B1 (en) | [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230616 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230616 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240515 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240813 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241017 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7590996 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |